<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03302156</url>
  </required_header>
  <id_info>
    <org_study_id>UW17017</org_study_id>
    <secondary_id>2017-0456</secondary_id>
    <secondary_id>A539300</secondary_id>
    <secondary_id>SMPH\RADIOLOGY\RADIOLOGY</secondary_id>
    <secondary_id>NCI-2018-00466</secondary_id>
    <secondary_id>06-08-2020</secondary_id>
    <nct_id>NCT03302156</nct_id>
  </id_info>
  <brief_title>PSMA PET and MRI in Gynecological Cancers</brief_title>
  <official_title>PSMA Positron Emission Tomography (PET) and Magnetic Resonance (MR) Imaging in Gynecological Cancers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Wisconsin, Madison</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Wisconsin, Madison</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this research is to determine the accuracy of PSMA positron emission tomography&#xD;
      (PET) and multi-parametric magnetic resonance (MR) imaging to detect the presence of&#xD;
      gynecological cancer cells in the body.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators will evaluate a novel second-generation low-molecular-weight prostate&#xD;
      specific membrane antigen (PSMA)-based positron emission tomography (PET) agent, 18F-DCFPyL,&#xD;
      to determine the presence or absence of cancer, the accurate distribution of cancer and the&#xD;
      normal biodistribution of PSMA in the abdomen and pelvis on PET imaging.&#xD;
&#xD;
      PSMA, also known as folate hydrolase 1 and glutamate carboxypeptidase II, is an enzyme&#xD;
      associated with prostate cancer but has been also found to be expressed in the tumor&#xD;
      neovasculature of many different types of non-prostate cancer tumors. PSMA-based 18F-DCFPyL&#xD;
      PET demonstrates very high tumor-to-background ratio when studied in other tumors, including&#xD;
      prostate tumors.&#xD;
&#xD;
      MR imaging is a highly sensitive and specific imaging modality that can be used for&#xD;
      gynecologic cancers. MR images can be obtained in conjunction with PSMA PET, adding&#xD;
      additional anatomic and multi-parametric MRI information without the need for a second&#xD;
      imaging appointment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    Due to COVID-19&#xD;
  </why_stopped>
  <start_date type="Actual">August 10, 2017</start_date>
  <completion_date type="Anticipated">August 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Diagnostic accuracy</measure>
    <time_frame>up to 1 day</time_frame>
    <description>Estimate the frequency with which PSMA PET and MR imaging and final IHC staining disagree in their classifications of presence of disease.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Biodistribution of PSMA</measure>
    <time_frame>up to 1 day</time_frame>
    <description>Record the normal biodistribution of PSMA as detected in normal female controls, by the resulting PET imaging.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiodosimetry of PSMA</measure>
    <time_frame>up to 1 day</time_frame>
    <description>The radiodosimetry of PSMA-based 18F-DCFPyL will be measured in normal female controls via the resulting PET images.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sensitivity and specificity of PSMA-based PET/MR</measure>
    <time_frame>up to 1 day</time_frame>
    <description>Record the distribution of PSMA in cancer tissue.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">52</enrollment>
  <condition>Gynecologic Cancer</condition>
  <arm_group>
    <arm_group_label>Healthy Control Non-Dosimetry Group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>The control group will consists of women with no imaging evidence of gynecological cancer, who are undergoing hysterectomy and salpingo-oophorectomy. Women will receive PSMA-based 18F-DCFPyL tracer and PET/MR imaging. n=6</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patient Group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>The patient group will consist of women with suspected gynecological cancers who are undergoing hysterectomy and salpingo-oophorectomy. Women will receive standard of care PSMA-based 18F-DCFPyL tracer and PET/MR imaging. n=40</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dosimetry Group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Women with or without suspected gynecological cancer. Women will receive PSMA-based 18F-DCFPyL tracer and PET/CT imaging, PET/MR imaging as needed. n=6</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PSMA-based 18F-DCFPyL PET tracer</intervention_name>
    <description>PSMA-based 18F-DCFPyL PET tracer that will be used to determine the presence or absence of cancer</description>
    <arm_group_label>Dosimetry Group</arm_group_label>
    <arm_group_label>Healthy Control Non-Dosimetry Group</arm_group_label>
    <arm_group_label>Patient Group</arm_group_label>
    <other_name>PSMA</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria for healthy female controls N=12 (includes up to 6 Dosimetry&#xD;
        participants):&#xD;
&#xD;
          -  Women with no suspected gynecological cancer.&#xD;
&#xD;
          -  No contraindications for MR or PET imaging.&#xD;
&#xD;
          -  Greater than or equal to 18 years of age.&#xD;
&#xD;
          -  Scheduled to undergo a hysterectomy and/or salpingo-oophorectomy&#xD;
&#xD;
        Inclusion Criteria for female controls (Dosimetry):&#xD;
&#xD;
          -  Women with or without suspected gynecological cancer.&#xD;
&#xD;
          -  No contraindications for MR or PET imaging.&#xD;
&#xD;
          -  Greater than or equal to 18 years of age.&#xD;
&#xD;
        Inclusion Criteria for gynecological cancer patients (N=40):&#xD;
&#xD;
          -  Women with known or suspected gynecological cancer&#xD;
&#xD;
          -  No contraindications for MR or PET imaging.&#xD;
&#xD;
          -  Greater than or equal to 18 years&#xD;
&#xD;
          -  Have had or are scheduled to undergo a hysterectomy and/or salpingo-oophorectomy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Women that are pregnant or breast-feeding.&#xD;
&#xD;
          -  Age &lt;18&#xD;
&#xD;
          -  Inability to provide informed consent on their own behalf&#xD;
&#xD;
          -  Severe kidney dysfunction (GFR &lt;30 mL/min/1.73m2)&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steve Cho, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Wisconsin, Madison</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Elizabeth Sadowski, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Wisconsin, Madison</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Wisconsin, Madison</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://cancer.wisc.edu/</url>
    <description>University of Wisconsin Carbone Cancer Center</description>
  </link>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>August 18, 2017</study_first_submitted>
  <study_first_submitted_qc>September 29, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 4, 2017</study_first_posted>
  <last_update_submitted>June 3, 2021</last_update_submitted>
  <last_update_submitted_qc>June 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Uterine cancer</keyword>
  <keyword>Ovarian cancer</keyword>
  <keyword>Hysterectomy</keyword>
  <keyword>Salpingo-oophorectomy</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

